• Publications
  • Influence
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, aExpand
  • 1,648
  • 70
  • PDF
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
BACKGROUND Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine,Expand
  • 486
  • 27
  • PDF
Chemoradiotherapy in malignant glioma: standard of care and future directions.
Glioma has been considered resistant to chemotherapy and radiation. Recently, concomitant and adjuvant chemoradiotherapy with temozolomide has become the standard treatment for newly diagnosedExpand
  • 429
  • 24
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
PURPOSE Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status mayExpand
  • 572
  • 23
  • PDF
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
PURPOSE The objectives of this study were to examine activation patterns of the phosphatidylinositol 3-kinase (PI3K) pathway in gliomas and to examine the prognostic significance of PI3K pathwayExpand
  • 338
  • 16
  • PDF
A multigene predictor of outcome in glioblastoma.
Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive fromExpand
  • 320
  • 14
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide
Overexpression of the epidermal growth factor receptor (EGFR) has been shown previously to correlate with enhanced malignant potential of many human tumor types, including glioblastoma multiformeExpand
  • 529
  • 12
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one of the most lethal of all cancers. Epidermal growth factor receptor (EGFR) mutations (EGFRvIII) andExpand
  • 228
  • 9
  • PDF
Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms
The observed radioresistance of human glioblastoma multiforme (GBM) poses a major challenge, which, if overcome, may lead to significant advances in the management of this patient population. ThereExpand
  • 197
  • 9
NFKBIA deletion in glioblastomas.
BACKGROUND Amplification and activating mutations of the epidermal growth factor receptor (EGFR) oncogene are molecular hallmarks of glioblastomas. We hypothesized that deletion of NFKBIA (encodingExpand
  • 127
  • 9
  • PDF